Bita Sehat
Investment Manager of Life Science @ Industrifonden
Bita Sehat is a Series B investor at Industrifonden focused on Health Care and Medical. Bita Sehat is the Investment Manager of Life Science at Industrifonden.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Bita Sehat invests in
Stages Bita Sehat invests in
Countries Bita Sehat invests in
Investment Focus
Industry
- Health Care 2 (50%)
- Medical 1 (25%)
- Wellness 1 (25%)
- Life Science 1 (25%)
- Biotechnology 1 (25%)
Stage
- Series B 1 (25%)
- Series C 1 (25%)
- Funding Round 1 (25%)
- Venture - Series Unknown 1 (25%)
Country
- Sweden 1 (25%)
- Denmark 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Minervax
|
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $57.4M / Oct 11, 2023 | |
|
Minervax
|
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $23.4M / Series C / Dec 15, 2022 | |
|
Minervax
|
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $52M / Series B / Dec 15, 2020 | |
Gesynta Pharma
|
Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se | $20.5M / Venture - Series Unknown / Jul 07, 2020 |
Co-Investors
About Industrifonden
Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.
Industrifonden Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anna Ljungdahl
Investment Manager
|
|||
|
Bita Sehat
Investment Manager of Life Science
|
|||
Hadar Cars
Senior Investment Director
|
|||
Hansson Lennart
Business Unit Manager Life Science
|
|||
Jonas Brambeck
Investment Manager - Life Science
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Bita Sehat invest in?
Bita Sehat invests primarily in Health Care, Medical and Wellness startups, most often at Series B and Series C stage. Most of the 4 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Bita Sehat last invest?
The most recent investment recorded for Bita Sehat closed in Oct 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
